Related Experiment Videos
What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?
G Brown1, B F Stewart, X Q Zhao
1Department of Medicine, University of Washington School of Medicine, Seattle, USA.
Insights
Intensive lipid-altering therapy may benefit patients with coronary artery disease and normal lipid levels if they have low high-density lipoprotein cholesterol or high apolipoprotein B. These factors, along with blood pressure and lipoprotein(a), predict treatment success.
Area of Science:
- Cardiology
- Atherosclerosis Research
- Lipid Metabolism
Background:
- Coronary artery disease (CAD) patients with normal lipid levels often face uncertainty regarding the benefits of intensive lipid-altering therapy.
- Understanding factors beyond total and low-density lipoprotein (LDL) cholesterol is crucial for optimizing treatment strategies in these individuals.
Purpose of the Study:
- To investigate the role of specific lipid and non-lipid variables in predicting the benefit of intensive lipid-altering therapy in normolipidemic CAD patients.
- To compare findings between the Familial Atherosclerosis Treatment Study (FATS) and the Harvard Atherosclerosis Reversibility Project (HARP).
Main Methods:
- Comparative analysis of normolipidemic subgroups from FATS and HARP.
- Evaluation of various lipid parameters (high-density lipoprotein cholesterol, apolipoprotein B) and other risk factors (systolic blood pressure, lipoprotein(a)).
Main Results:
- Low high-density lipoprotein cholesterol (HDL-C) levels significantly increase the likelihood of benefit from intensive lipid-altering therapy.
- Elevated apolipoprotein B (ApoB) levels also strongly predict a positive response to lipid-altering interventions.
- Systolic blood pressure and lipoprotein(a) levels further contribute to risk prediction and potential treatment benefit.
Conclusions:
- In normolipidemic CAD patients, HDL-C and ApoB levels are key predictors of response to intensive lipid-altering therapy.
- These findings suggest that a broader assessment of lipid profiles and cardiovascular risk factors is necessary for personalized treatment approaches.
- Further research can refine risk stratification and treatment selection for CAD patients with normal baseline lipid levels.
Abstract:
Controversy still remains regarding the possible clinical or arteriographic benefit of intensive lipid-altering therapy in patients who have coronary artery disease and apparently normal lipid levels. Resolution of this controversy appears to depend on an improved understanding of the role of variables other than total or low density lipoprotein cholesterol levels. A comparison of the "normolipidemic" subgroup of The Familial Atherosclerosis Treatment Study patients and The Harvard Atherosclerosis Reversibility Project patients indicates that low levels of high density lipoprotein cholesterol and elevated levels of apolipoprotein B appear to increase considerably the likelihood of benefit from intensive lipid-altering therapy. Other risk-related variables such as systolic blood pressure and lipoprotein(a) further contribute to the prediction of risk and possibly to the potential for treatment benefit.